Contrasting Amneal Pharmaceuticals (NASDAQ:AMRX) and Lotus Pharmaceuticals (OTCMKTS:LTUS)

Amneal Pharmaceuticals (NASDAQ:AMRX) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for Amneal Pharmaceuticals and Lotus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0	2	6	0	2.75
Lotus Pharmaceuticals	0	0	0	0	0.00

Amneal Pharmaceuticals currently has a consensus price target of $15.00, suggesting a potential upside of 17.00%. Given Amneal Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Amneal Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -1.8, meaning that its share price is 280% less volatile than the S&P 500.

Profitability

This table compares Amneal Pharmaceuticals and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	2.39%	-228.24%	6.91%
Lotus Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares Amneal Pharmaceuticals and Lotus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02 billion	1.34	$72.06 million	$0.23	55.74
Lotus Pharmaceuticals	N/A	N/A	-$30,000.00	N/A	N/A

Amneal Pharmaceuticals has higher revenue and earnings than Lotus Pharmaceuticals.

Insider & Institutional Ownership

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats Lotus Pharmaceuticals on 10 of the 11 factors compared between the two stocks.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.